Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Bristol-Myers

Takeda Pharmaceutical

It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again.

4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows

Apple

Accenture Plc

Automatic Data Processing

CME Group

Costco

Cisco Systems

General Dynamics

Home Depot

Honeywell

Intel

Johnson & Johnson

Eli Lilly

Lockheed Martin

Mastercard

Medtronic

Microsoft

NIKE

PepsiCo

Procter & Gamble

Stryker

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

Colgate-Palmolive

Enterprise Products Partners

Gladstone Investment

Interpublic Group of Companies

LTC Properties

Main Street Capital

MetLife

People's United Financial

iShares Preferred and Income Securities ETF 

Prudential Financial

Shaw Communications

STAG Industrial

Unum

Verizon

Exxon Mobil

From May to December 2020, Kiplinger Today listed five sets of dividend stocks sorted as favorites, super-safe, durable, centenarian, and MoPays. Those five "outstanding dividend" articles revealed 56 equities. Kiplinger article titles were, 'Dividend15: Our Favorites'; '15 Super-Safe Dividends'; '7 Durable Distributions'; '13 100+Year Dividends'; '11 Monthly-Pay Stocks/Funds.'

Kiplinger Outstanding August Dividend Dogs Feature 9 Primed To Buy

Pfizer

Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?

Amgen

A handful of healthcare giants are some of the few Dow stocks in the red so far today, as federal data underpins the prospects of a continued economic recovery.

Healthcare Stock Sell-Off Keeps the Dow Jones From Reaching Record Levels

Merck & Co., Inc. (MRK) CEO Rob Davis on Q2 2021 Results - Earnings Call Transcript

Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.

Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer

Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer

Strong revenue from cancer treatment Keytruda stood out in Merck's results, with analysts highlighting upside to sales estimates for the drug.

Merck Sales Beat Estimates, But the Stock Fell. Here's 1 Reason to Be Bullish.

Merck (MRK) delivered earnings and revenue surprises of 0.77% and 1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Q2 Earnings and Revenues Surpass Estimates

Merck & Co Inc (NYSE: MRK) Q2 sales reached $11.4 billion, +22% Y/Y, missing the consensus of $11.5 billion. Excluding the foreign exchange impact, revenues were up 19%, reflecting ongoing recovery from the COVID-19 pandemic and underlying solid demand.

Merck Stock Falls As Q2 Earnings Lag Wall Street Estimates, Trimmed FY21 Guidance Below Consensus

Shares of Merck & Co. Inc. fell 0.9% in premarket trading Thursday, after the drug maker reported second-quarter adjusted profit that matched expectations, while sales rose above forecasts even as Keytruda sales came up short. Net income fell to $1.55 billion, or 61 cents a share, from $3.00 billion, or $1.18 a share, in the year-ago period.

Merck stock slips after adjusted profit matches expectations, while revenue beats

Merck & Co Inc on Thursday reported a 49% fall in second-quarter profit after it spun off its women's health and biosimilar assets into Organon in June.

Merck profit nearly halves on Organon spin off

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2021 Financial Results

Merck Announces Second-Quarter 2021 Financial Results

Merck is scheduled to report its Q2 2021 results on Thursday, July 29. We expect the company to likely post revenue and earnings above the consensus estimates, led by continued expansion of Keytruda, and a recovery in the company's vaccine sales, primarily Gardasil, as well as the animal.

Earnings Beat In Cards For Merck's Q2?

AstraZeneca

Comcast

Three of the five largest U.S. traded companies will report June-quarter earnings after markets close Tuesday.

Earnings Previews: AstraZeneca, Comcast, Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter 2021 Dividend

Merck Announces Fourth-Quarter 2021 Dividend

Why 1 Biotech Stock Could Be On Watch After Merck's Keytruda Gets FDA Nod. The post Biotech Stocks Are In Focus After Merck's FDA Approval & 1 Stands Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Stocks Are In Focus After Merck's FDA Approval & 1 Stands Out

McDonald's

Domino's Pizza

With the trading day more than halfway over, the broad markets were sliding, with the Nasdaq leading the way with a retreat of nearly 2%.

Domino's, Eli Lilly, McDonald's, Merck and More Tuesday Afternoon Analyst Upgrades and Downgrades

Merck & Co Inc (NYSE: MRK) has announced overall survival (OS) results from Phase 3 KEYNOTE-355 trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). Final analysis show first-line treatment with Keytruda/Chemo combo demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone in patients with mTNBC whose tumors expressed PD-L1.

Merck's Keytruda Combo Trial Meets Overall Survival Endpoint In PD-L1 Expressing Breast Cancer Patients

The FDA has approved Merck & Co Inc (NYSE: MRK) immunotherapy Keytruda (pembrolizumab) to treat an early form of breast cancer in combination with chemotherapy. The FDA approval is for treating triple-negative breast cancer (TNBC), an aggressive form of the disease with an increased risk of recurrence.

FDA Approves Merck's Keytruda/Chemo Combo For Early Breast Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck Announces Phase 3 KN-355 Trial Met Primary Endpoint of OS in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1

Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA for Patients With High-Risk Early-Stage TNBC as Neoadjuvant Treatment with Chemo, Then Continued as Single Agent After Surgery

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that Hong Chow will join its Healthcare business sector as Head of China & International on October 1. In this role at Merck, Chow will lead China, Japan as well the regions Europe, Latin America, Asia-Pacific and Middle East, Africa and Russia, the franchise of Cardiovascular Metabolism & Endocrinology (CM&E), and the Global Business Innovation team. Chow will report to Peter Guent

Merck Announces Appointment of Head of China & International for Healthcare

News for Merck Stock (MRK)